0
Merck & Co., Inc. (MRK): director Paul J. Diaz elected to the board
MRK · NYSE · Pharmaceutical Preparations · Large accelerated filer · NJ · Form 8-K filed 2026-10-13
Paul J. Diaz elected to Board of Directors effective November 1, 2026, appointed to Audit and Research Committees.
Board election
Events in this filing
1 event: Board election (Director).
Names, stated reasons, successor status, compensation terms and the evidence quotes are shown to subscribers. See plans
Item 5.02 as filed
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026. The Board appointed Mr. Diaz as a member of both the Audit Committee and the Research Committee of the Board. For his service on the Board, Mr. Diaz will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2026. Mr. Diaz has no arrangements or understandings with any other person pursuant to which he was elected to the Board, nor does he have a relationship or related transaction with the Company that would require disclosure pursuant to Item 404(a) of Regulation S-K of the Securities and Exchange Commission in connection with his appointment as a director of the Company.Source filing on EDGAR →